YOQNEAM, Israel and SAN RAMON, California, January 9 /PRNewswire/ -- Renowned plastic surgeons and dermatologists from Europe, the Middle East, Asia and the Americas will present their latest findings from clinical experience with UltraShape during the 10th annual IMCAS meeting held in Paris, France from January 9th - 12th, 2008.
UltraShape is the clinically proven non-invasive solution for fat reduction and body contouring using "non-thermal" selective focused ultrasound technology. Seven leading physicians specializing in the field of aesthetic medicine will present clinical results on the effectiveness of UltraShape's Contour I in reducing fat thickness and improving body contours.
Dr. Benjamin Ascher, Clinique of Aesthetic Surgery IENA in Paris, France, and Course Director of IMCAS, will present his most recent clinical experience involving 130 patients. Results demonstrate that following a three-treatment protocol using the UltraShape Contour I system, over 72% of patients achieved 2-7 cm in body circumference reduction. "Both my patients and I, as a physician, have been extremely satisfied with the results. Patients are specifically pleased with the pain-free, 'walk-in, walk out' nature of the procedure and the long-lasting body contouring effects," affirmed Dr. Ascher.
Dr. Christopher Inglefield, Plastic Surgery Clinic at the London Bridge Hospital in London, UK, will review results from his 500-patient clinical experience with UltraShape Contour I, in which he found an average circumference reduction of 6.3 cm and a patient satisfaction rate of 93%. "UltraShape's innovative technology has proven to be a breakthrough in the medical aesthetics field. Adding this unique non-invasive technology to my practice has attracted a significant amount of new non-surgical patients to my clinic," stated Dr. Inglefield.
Dr. Hector Leal-Silva, Center for Dermatology and Cosmetic Surgery (CDCC) in Monterrey, Mexico, will discuss his clinical experience with UltraShape which showed definite measurable results after three treatments in 100% of patients, including an average of a 5 cm reduction in circumference and documented CT scan reduction of fat thickness. Ninety-four percent (94%) of patients were satisfied with the procedure. "UltraShape has addressed a previously unmet patient need in my practice for a safe and effective non-invasive option for the reduction of localized fat deposits," said Leal.
Other physicians presenting clinical results with UltraShape at IMCAS include:
- Dr. Michael Scheflan, M.D., Plastic Surgeon, Atidim Medigroup, Israel
- Dr. Wichai Hongcharu, Head of the Department of Dermatology at the Saint Louis Hospital, Bangkok, Thailand
- Dr. Jana Hercogova MD, PhD, from Charles University and Bulovka University Hospital in Prague, CZ
- Dr. Dean Ad-El, Head of the Department of Plastic Surgery at Rabin Medical Center, Israel
Rodger Stewart, UltraShape CEO stated, "UltraShape is honored to be participating, for the third time, in IMCAS, which has become a major international meeting showcasing the latest innovations in medical aesthetics. We are pleased that these independent studies continue to reinforce UltraShape findings and are encouraged by the increasing amount of clinical data that affirms UltraShape's effectiveness and patient satisfaction. The continual positive response from both physicians and patients is a testament to our unique technology and confirms our leadership position in non-invasive fat reduction and body contouring."
The International Master Course on Aging Skin (IMCAS) has become one of the largest, most influential and most representative of international conferences dedicated to the field of aesthetic surgery and cosmetic dermatology. By welcoming 2,600 delegates in each of our annual conferences coming from 40 different countries, it represents a true "medical population sampling." Its principal objective: the promotion of highest possible standards in clinical practice, education and research in the plastic surgery - dermatology interface discipline or related disciplines (facial plastic surgery, oculoplastic surgery, aesthetic medicine, research, etc...)For more information visit http://www.imcas.com
About the UltraShape CONTOUR I
The UltraShape Contour I system, based on patented focused ultrasound technology, is the first scientifically and clinically proven non-invasive fat reduction and body contouring solution for both men and women. The device produces mechanical, non-thermal, acoustic effects which targets and selectively destroys fat cells, leaving surrounding critical structures such as skin, blood vessels, nerves, and connective tissue intact. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software guarantees adherence to a pre-determined treatment algorithm minimizing risk of contour irregularities, a common side effect of liposuction. The UltraShape procedure is performed during a convenient, "walk-in, walk-out" session carried out in an office-based environment; it requires no anesthesia or sedation, and the vast majority of patients report no pain or discomfort. After treatment, patients immediately resume their daily routines with no need for maintenance treatments. The UltraShape procedure is available in 50 countries and over 50,000 patient treatments have been performed worldwide with high patient satisfaction. The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The UltraShape Contour I system is not available for sale in the United States.
UltraShape is redefining aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for body contouring. The company is dedicated to providing clinically proven safe and effective solutions that enhance the lives of patients worldwide. The UltraShape proprietary non-invasive body contouring technology is based on focused ultrasound that targets and selectively disrupts fat cells without affecting surrounding structures. Founded in 2000, UltraShape is a privately held and venture backed company with offices in the United States, Israel, France, United Kingdom, and Italy. For more information visit http://www.ultrashape.com.
Abigail Marks UltraShape +972-4-909-4029 firstname.lastname@example.org Paula Moggio FischerHealth +1-310-577-7870 x151 email@example.com Jessica Fishman Gitam Porter Novelli +972-3-576-5798 firstname.lastname@example.org
Abigail Marks, UltraShape, +972-4-909-4029, email@example.com; Paula Moggio, FischerHealth, +1-310-577-7870 x151, firstname.lastname@example.org; Jessica Fishman, Gitam Porter Novelli, +972-3-576-5798, email@example.com